Volume 12, Number 1—January 2006
Research
Economics of Neuraminidase Inhibitor Stockpiling for Pandemic Influenza, Singapore
Table 4
Outcomes by age and risk groups*
Risk and age group, y | Strategy option | Stockpile cost (1 cycle, million $) | Mean lives saved compared with no action | Mean cost per life saved compared with no action (million $) | Mean benefit compared with no action (million $) |
---|---|---|---|---|---|
Low risk, age <1–19 | No action | NA | Deaths: 17 | NA | Cost: 122 |
Only Rx † | 17 | 8 | Dominates§ | 87 | |
12 wk ‡ | 251 | 11 | 41 | –315 | |
24 wk ‡ | 485 | 14 | 70 | –717 | |
Low risk, age 20–64 | No action | N/A | Deaths: 42 | N/A | Cost: 507 |
Only Rx | 49 | 21 | Dominates§ | 382 | |
12 wk | 741 | 29 | 40 | –808 | |
24 wk | 1,433 | 36 | 73 | –1,999 | |
Low risk, age >65 | No action | NA | Deaths: 185 | NA | Cost: 57 |
Only Rx | 3 | 60 | Dominates§ | 28 | |
12 wk | 49 | 108 | 0.9 | –43 | |
24 wk | 95 | 148 | 1.3 | –115 | |
High risk, age >1–19 | No action | NA | Deaths: 92 | NA | Cost: 186 |
Only Rx | 2 | 45 | Dominates§ | 94 | |
12 wk | 28 | 63 | 1.0 | 83 | |
24 wk | 54 | 78 | 1.8 | 66 | |
High risk, age 20–64 | No action | NA | Deaths: 220 | NA | Cost: 443 |
Only Rx | 6 | 109 | Dominates§ | 235 | |
12 wk | 85 | 153 | 1.1 | 175 | |
24 wk | 165 | 189 | 2.0 | 100 | |
High risk, age >65 | No action | NA | Deaths: 547 | NA | Cost: 117 |
Only Rx | 2 | 179 | Dominates§ | 44 | |
12 wk | 29 | 321 | 0.17 | 24 | |
24 wk | 55 | 438 | 0.25 | 0.1 |
*Mean values are shown, with all costs in 2004 Singapore dollars; NA, not applicable.
†Only Rx refers to treatment-only, without prophylaxis.
‡12 and 24 wk refer to number of weeks of prophylaxis for the respective risk and age groups.
§Treatment-only dominates no action because treatment-only saves lives and is less costly overall.
1"Dominate" is a term used in cost-effectiveness analyses and refers to a strategy that is both more efficacious and less costly than another strategy.
Page created: February 16, 2012
Page updated: February 16, 2012
Page reviewed: February 16, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.